Alnylam Pharma: Hold Rating Amid Strong Sales and Elevated Costs

Leerink Partners analyst Mani Foroohar has maintained their neutral stance on ALNY stock, giving a Hold rating on August 1.

Mani Foroohar has given his Hold rating due to a combination of factors surrounding Alnylam Pharma’s recent performance and future prospects. The company’s second-quarter results for 2025 showed impressive sales figures, particularly for Amvuttra, which exceeded market expectations. This strong performance was bolstered by a significant number of patients on therapy and recent regulatory approvals in several major markets.
Despite these positive developments, the Hold rating reflects a cautious approach due to the company’s ongoing high research and development expenses and selling, general, and administrative costs, which were above consensus estimates. Additionally, while the raised guidance for fiscal year 2025 indicates a positive outlook, the elevated expectations and competitive landscape in the biotech sector suggest a balanced risk-reward profile for investors at this time.

In another report released on August 1, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $422.00 price target.

ALNY’s price has also changed dramatically for the past six months – from $271.310 to $392.240, which is a 44.57% increase.